Lexicon Pharmaceuticals Inc. [NASDAQ: LXRX] closed the trading session at $1.94 on 07/31/20. The day’s price range saw the stock hit a low of $1.80, while the highest price level was $1.94. The company report on July 30, 2020 that Lexicon Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program.
Phase 2 Study for Diabetic Peripheral Neuropathic Pain Underway, Additional Studies Planned in Other Areas of Neuropathic Pain.
Sale of XERMELO to TerSera to Yield Up to $224 Million in Upfront and Milestone Payments Plus Mid-Teens Royalties on Net Sales of XERMELO in Biliary Tract Cancer.
The stocks have a year to date performance of -53.25 percent and weekly performance of 12.14 percent. The stock has been moved at -37.22 percent over the last six months. The stock has performed -3.48 percent around the most recent 30 days and changed 2.11 percent over the most recent 3-months.
If compared to the average trading volume of 1.65M shares, LXRX reached to a volume of 2614975 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Lexicon Pharmaceuticals Inc. [LXRX]:
Gabelli & Co have made an estimate for Lexicon Pharmaceuticals Inc. shares, keeping their opinion on the stock as Hold, with their previous recommendation back on December 11, 2019. While these analysts kept the previous recommendation, Citigroup raised their target price from $3 to $4. The new note on the price target was released on November 08, 2019, representing the official price target for Lexicon Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $3, while Gabelli & Co analysts kept a Buy rating on LXRX stock. On July 29, 2019, analysts decreased their price target for LXRX shares from 10 to 4.
The Average True Range (ATR) for Lexicon Pharmaceuticals Inc. is set at 0.16, with the Price to Sales ratio for LXRX stock in the period of the last 12 months amounting to 0.67.
LXRX stock trade performance evaluation
Lexicon Pharmaceuticals Inc. [LXRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 12.14. With this latest performance, LXRX shares dropped by -3.48% in over the last four-week period, additionally sinking by -37.22% over the last 6 months – not to mention a rise of 48.09% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LXRX stock in for the last two-week period is set at 51.68, with the RSI for the last a single of trading hit 53.38, and the three-weeks RSI is set at 50.21 for Lexicon Pharmaceuticals Inc. [LXRX]. The present Moving Average for the last 50 days of trading for this stock 1.9437, while it was recorded at 1.8320 for the last single week of trading, and 2.7989 for the last 200 days.
Lexicon Pharmaceuticals Inc. [LXRX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Lexicon Pharmaceuticals Inc. [LXRX] shares currently have an operating margin of +52.81 and a Gross Margin at +98.42. Lexicon Pharmaceuticals Inc.’s Net Margin is presently recorded at +40.40.
Return on Total Capital for LXRX is now 58.39, given the latest momentum, and Return on Invested Capital for the company is 45.67. Return on Equity for this stock inclined to 286.97, with Return on Assets sitting at 36.63. When it comes to the capital structure of this company, Lexicon Pharmaceuticals Inc. [LXRX] has a Total Debt to Total Equity ratio set at 210.83. Additionally, LXRX Total Debt to Total Capital is recorded at 67.83, with Total Debt to Total Assets ending up at 58.52. Long-Term Debt to Equity for the company is recorded at 200.91, with the Long-Term Debt to Total Capital now at 64.64.
Reflecting on the efficiency of the workforce at the company, Lexicon Pharmaceuticals Inc. [LXRX] managed to generate an average of $707,245 per employee. Receivables Turnover for the company is 10.31 with a Total Asset Turnover recorded at a value of 0.91.Lexicon Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.50 and a Current Ratio set at 2.50.
Earnings per share (EPS) analysis for Lexicon Pharmaceuticals Inc. [LXRX] stock
With the latest financial reports released by the company, Lexicon Pharmaceuticals Inc. posted 1.95/share EPS, while the average EPS was predicted by analysts to be reported at 0.73/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 167.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LXRX.
Lexicon Pharmaceuticals Inc. [LXRX]: Insider Ownership positions
There are presently around $203 million, or 98.70% of LXRX stock, in the hands of institutional investors. The top three institutional holders of LXRX stocks are: ARTAL GROUP S.A. with ownership of 60,240,864, which is approximately 0% of the company’s market cap and around 1.40% of the total institutional ownership; FMR LLC, holding 12,321,594 shares of the stock with an approximate value of $23.9 million in LXRX stocks shares; and ULYS, L.L.C., currently with $8.38 million in LXRX stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Lexicon Pharmaceuticals Inc. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 60 institutional holders increased their position in Lexicon Pharmaceuticals Inc. [NASDAQ:LXRX] by around 6,483,024 shares. Additionally, 51 investors decreased positions by around 9,389,374 shares, while 29 investors held positions by with 88,872,100 shares. The mentioned changes placed institutional holdings at 104,744,498 shares, according to the latest SEC report filing. LXRX stock had 21 new institutional investments in for a total of 1,110,492 shares, while 24 institutional investors sold positions of 6,004,856 shares during the same period.